Pharmaceutical Fill and Finish Outsourcing Market Report 2026

The pharmaceutical fill and finish outsourcing market size has grown strongly in recent years. It will grow from $3.77 billion in 2025 to $4.09 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to growing biologics production volumes, increasing complexity of injectable formulations, limited in-house manufacturing capacity, high capital cost of fill and finish equipment, rising demand for contract manufacturing services.

The pharmaceutical fill and finish outsourcing market size is expected to see strong growth in the next few years. It will grow to $5.76 billion in 2030 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increasing vaccine and biologics pipeline expansion, rising preference for scalable outsourcing models, growing investments in advanced aseptic technologies, expansion of personalized medicine production, increasing regulatory scrutiny on manufacturing quality. Major trends in the forecast period include increasing outsourcing of sterile fill and finish operations, rising demand for high-speed automated filling lines, expansion of single-use filling technologies, growing focus on regulatory compliance expertise, adoption of flexible manufacturing capacity models.

The rising demand for biologic drugs is expected to drive the growth of the pharmaceutical fill and finish outsourcing market in the coming years. Biologic drugs, also referred to as biologics or biosimilars, are pharmaceutical products developed from living organisms or containing components derived from living sources. By outsourcing the fill and finish stage to contract manufacturing organizations (CMOs), drug manufacturers can leverage specialized expertise and advanced infrastructure, enabling pharmaceutical companies to concentrate on biologic drug development, research, and scale-up while relying on CMOs for efficient and cost-effective filling and finishing operations. For instance, in April 2025, according to Hardman and Co., a UK-based independent investment research and corporate advisory firm, the US Food and Drug Administration approved 63 new chemical entities and biologics in 2024, compared to 53 approvals in 2023. Therefore, the increasing demand for biologic drugs is supporting the growth of the pharmaceutical fill and finish outsourcing market.

Major companies operating in the pharmaceutical fill and finish outsourcing market are emphasizing the development of sustainable packaging materials and environmentally responsible methods to reduce carbon footprints and support environmental conservation. Sustainable packaging involves designing and using packaging solutions that minimize environmental impact throughout the product lifecycle. For example, in November 2023, Amcor, an Australia-based pharmaceutical packaging company, introduced next-generation Healthcare Recycle-Ready Medical Laminates. These all-film packaging solutions are designed to meet medical device performance requirements while reducing overall carbon footprint and enabling recyclability within the polyethylene stream. The monomaterial polyethylene laminate can replace non-recyclable lidding in various packaging formats, including 3D thermoformed packages used for products such as drapes, protective materials, catheters, injections, and tubing systems.

In January 2023, Life Science Outsourcing Inc., a US-based contract manufacturing and value-added services company, acquired J-Pac Medical for an undisclosed amount. This acquisition expanded Life Science Outsourcing’s service portfolio, strengthened manufacturing capacity, and supported entry into biomaterials and diagnostics end markets. J-Pac Medical is a US-based medical device and diagnostic manufacturing and packaging outsourcing partner specializing in assembly, packaging, sterilization, and diagnostic services.

Major companies operating in the pharmaceutical fill and finish outsourcing market are Groninger and Co. GmbH, Wockhardt Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Recipharm AB, Lonza Group AG, Catalent Inc., Dr. Reddys Laboratories Ltd., West Pharmaceutical Services Inc., Sun Pharmaceutical Industries Ltd., Patheon N.V., Piramal Enterprises Ltd., Gerresheimer AG, CordenPharma International, Fujifilm Diosynth Biotechnologies, Optima Packaging Group GmbH, Jubilant HollisterStier LLC., Ajinomoto Bio-Pharma Services, Cytovance Biologics Inc., Grand River Aseptic Manufacturing, Baxter Pharmaceutical Solutions LLC., Halo Pharma Inc., MabPlex Inc., August Bioservices, Siegfried Holding AG, Aenova Group, SK Pharmteco, Recro Pharma.

North America was the largest region in the pharmaceutical fill and finish outsourcing market in 2025. The regions covered in the pharmaceutical fill and finish outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical fill and finish outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the pharmaceutical fill and finish outsourcing market by increasing costs of imported filling machinery, isolators, sterilization systems, and packaging components required for aseptic operations. Contract manufacturing facilities in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces higher capital expenditure for capacity expansion. These tariffs are raising service pricing and extending equipment procurement timelines. At the same time, they are encouraging regional manufacturing investments, local equipment sourcing, and expansion of domestic fill and finish capabilities.

The pharmaceutical fill and finish outsourcing market research report is one of a series of new reports that provides pharmaceutical fill and finish outsourcing market statistics, including pharmaceutical fill and finish outsourcing industry global market size, regional shares, competitors with a pharmaceutical fill and finish outsourcing market share, detailed pharmaceutical fill and finish outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical fill and finish outsourcing industry. This pharmaceutical fill and finish outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical fill and finish outsourcing involves contracting specialized pharmaceutical manufacturing organizations to perform filling and sealing operations of drug products into final containers while ensuring appropriate sterility and accuracy. These services are used by pharmaceutical and biopharmaceutical companies to access skilled personnel, expensive automated equipment, compliance with strict regulatory inspections, improved operational efficiency, and greater flexibility in production capacity.

The primary types of pharmaceutical fill and finish outsourcing products include liquids, solids, and semi-solids. Liquid formulations are pourable pharmaceutical products composed of active drug or chemical ingredients combined with non-drug or inert components. These products are processed from organic substances derived from animal sources, organic substances obtained from microorganisms, and inorganic substances, and are utilized by pharmaceutical and biopharmaceutical companies.

The pharmaceutical fill and finish outsourcing market includes revenues earned by entities by providing outsourcing of aseptic or sterile filling and finishing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.